Novel drugs, including the histone deacetylase (HDAC) inhibitors, romidepsin, and belinostat, have been approved for patients with relapsed or refractory PTCL in recent years [12, 13]. Here, HDAC9 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.